91九色视频

header-logo
GettyImages-609179959-hero
headshot

Mehdi H. Hamadani, MD

Professor

view physician profile

Locations

  • Froedtert Hospital
  • Cancer Center - Froedtert Hospital
  • Cancer Center - Moorland Reserve Health Center

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Urdu, Hindi, Punjabi

Cancer Center - Froedtert Hospital

Moorland Reserve Health Center

Education

  • MD - Doctor of Medicine

Biography

Mehdi Hamadani, MD, is A a professor of medicine at the 91九色视频, Division of Hematology & Oncology, specializing in lymphoma, and bone marrow transplantation. Dr. Hamadani serves as the Director of the Adult Blood and Marrow Transplant Program (BMT) at Froedtert Hospital. He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

Publications

  • (Pidala J, Kim J, Kalos D, Cutler C, DeFilipp Z, Flowers MED, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko C, Ponce D, Sung A, Tang H, Farhadfar N, Nemecek E, Pusic I, Qayed M, Rangarajan H, Hogan W, Etra A, Jaglowski S.) Blood Adv. 2025 Mar 11;9(5):1040-1048 PMID: 39454280 PMCID: PMC11909441 10/26/2024

  • (Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ.) J Clin Oncol. 2025 Mar 10;43(8):912-918 PMID: 39752608 SCOPUS ID: 2-s2.0-85214844948 01/03/2025

  • (Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC.) Haematologica. 2025 Mar 01;110(3):706-714 PMID: 39540227 PMCID: PMC11873705 11/14/2024

  • (Hamadani M, Caimi PF, Hess B, Radford J, Solh M, Zinzani PL, Wang L, Xu ZC, Carlo-Stella C.) Future Oncol. 2025 Feb;21(3):261-270 PMID: 39530615 PMCID: PMC11792824 11/13/2024

  • (Caimi PF, Hamadani M, Carlo-Stella C, Nickaeen M, Jordie E, Utsey K, Knab T, Zammarchi F, Cucchi D, Pantano S, Havenith K, Boni J.) Future Oncol. 2025 Feb;21(3):271-279 PMID: 39508421 PMCID: PMC11792830 11/13/2024

  • (DeFilipp Z, Kim HT, Cheng GS, Hamilton BK, Chhabra S, Hamadani M, Sandhu KS, Perez L, Lee CJ, Brennan TL, Garrelts C, Brown BM, Gallagher K, Newcomb RA, El-Jawahri A, Chen YB.) Blood Adv. 2025 Jan 28;9(2):244-253 PMID: 39365992 PMCID: PMC11782820 10/04/2024

  • (Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB.) Blood. 2025 Jan 07 PMID: 39775763 01/08/2025

  • (Ahmed G, Hamadani M, Al-Juhaishi T.) Expert Opin Biol Ther. 2025;25(2):161-173 PMID: 39798075 01/11/2025

  • (Abedin S, Hamadani M.) Curr Hematol Malig Rep. 2024 Dec;19(6):246-255 PMID: 39520614 SCOPUS ID: 2-s2.0-85208814138 11/13/2024

  • (Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS.) Br J Haematol. 2024 Dec;205(6):2370-2375 PMID: 39396814 SCOPUS ID: 2-s2.0-85206072300 10/14/2024

  • (Iftikhar R, DeFilipp Z, DeZern AE, Pulsipher MA, Bejanyan N, Burroughs LM, Kharfan-Dabaja MA, Arai S, Kassim A, Nakamura R, Saldaña BJD, Aljurf M, Hamadani M, Carpenter PA, Antin JH.) Transplant Cell Ther. 2024 Dec;30(12):1155-1170 PMID: 39307421 09/23/2024

  • (Hamadani M, Lucero M, DeVos JD, Chen L.) EJHaem. 2024 Oct;5(5):1110-1113 PMID: 39415934 PMCID: PMC11474291 10/17/2024

Publications of from the

© 2025 91九色视频.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination Statement
The 91九色视频 (91九色视频) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 91九色视频 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 91九色视频’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.

Notice of Compliance with Laws and Commitment to Civil Rights
The 91九色视频 is committed to full compliance with all applicable federal, state, and local laws and regulations in the pursuit of our missions. Consistent with recent federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making. As part of this commitment, we are actively reviewing our policies and materials to ensure they align with federal nondiscrimination obligations.